Sentences with phrase «manufacturers in product liability litigation»

Except for a brief, misguided trip to the «dark side,» Rachel has spent her whole career defending drug and device manufacturers in product liability litigation and in government actions arising from such litigation.

For more than 25 years, John has defended manufacturers in product liability litigation in trial and appellate courts involving a multitude of products ranging from ATVs and RVs to suction vibrasorbers.

Defended aircraft manufacturer in product liability litigation in state and federal courts arising from fatal crashes in general aviation.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Many factors could cause BlackBerry's actual results, performance or achievements to differ materially from those expressed or implied by the forward - looking statements, including, without limitation: BlackBerry's ability to enhance its current products and services, or develop new products and services in a timely manner or at competitive prices, including risks related to new product introductions; risks related to BlackBerry's ability to mitigate the impact of the anticipated decline in BlackBerry's infrastructure access fees on its consolidated revenue by developing an integrated services and software offering; intense competition, rapid change and significant strategic alliances within BlackBerry's industry; BlackBerry's reliance on carrier partners and distributors; risks associated with BlackBerry's foreign operations, including risks related to recent political and economic developments in Venezuela and the impact of foreign currency restrictions; risks relating to network disruptions and other business interruptions, including costs, potential liabilities, lost revenues and reputational damage associated with service interruptions; risks related to BlackBerry's ability to implement and to realize the anticipated benefits of its CORE program; BlackBerry's ability to maintain or increase its cash balance; security risks; BlackBerry's ability to attract and retain key personnel; risks related to intellectual property rights; BlackBerry's ability to expand and manage BlackBerry ® World ™; risks related to the collection, storage, transmission, use and disclosure of confidential and personal information; BlackBerry's ability to manage inventory and asset risk; BlackBerry's reliance on suppliers of functional components for its products and risks relating to its supply chain; BlackBerry's ability to obtain rights to use software or components supplied by third parties; BlackBerry's ability to successfully maintain and enhance its brand; risks related to government regulations, including regulations relating to encryption technology; BlackBerry's ability to continue to adapt to recent board and management changes and headcount reductions; reliance on strategic alliances with third - party network infrastructure developers, software platform vendors and service platform vendors; BlackBerry's reliance on third - party manufacturers; potential defects and vulnerabilities in BlackBerry's products; risks related to litigation, including litigation claims arising from BlackBerry's practice of providing forward - looking guidance; potential charges relating to the impairment of intangible assets recorded on BlackBerry's balance sheet; risks as a result of actions of activist shareholders; government regulation of wireless spectrum and radio frequencies; risks related to economic and geopolitical conditions; risks associated with acquisitions; foreign exchange risks; and difficulties in forecasting BlackBerry's financial results given the rapid technological changes, evolving industry standards, intense competition and short product life cycles that characterize the wireless communications industry.

With deep experience in product liability matters and class action litigation, including catastrophic injury and wrongful death cases, as well as consumer fraud, he represents national and international companies, including manufacturers of motor vehicles, power tools, pharmaceuticals, clothing, glass products, outdoor power equipment, and industrial machinery.

We regularly defend automobile, heavy truck, bus, locomotive, and aircraft manufacturers — as well as their component suppliers — in high - stakes product liability, commercial, and catastrophic injury litigation.

Our litigation and trial lawyers are experienced with the common and statutory laws involving the prospective liability of manufacturers, distributors, and sellers of products to purchasers, users, and bystanders for personal injury and property damage caused by alleged defects in those products.

In Mixed Ruling for Food Manufacturers, the Ninth Circuit Affirms Decertification of Damages Class While Keeping Door Open for Individual Claims - Product Liability Litigation Update

Langdon & Emison's reputation as a national leader in auto product liability litigation comes from 30 years of taking on the world's largest auto manufacturers in courtrooms from coast to coast, including the U.S. Supreme Court.

Represented a Korean tire manufacturer in litigation with its U.S. insurance broker with respect to acquisition of product liability insurance and in employment related class action litigation

Defense of leading U.S. pharmaceutical and biologic manufacturers in national and international product liability and commercial litigation involving prescription biologics, nonsteroidal pain medications, diet drugs, statins and other medications, including class actions, multi-district litigations, Congressional investigations, criminal proceedings, and shareholder derivative litigation

Her litigation experience stretches across numerous industries, including the defense of product manufacturers, corporations, banks, financing institutions, premises owners and individuals in product liability and business litigation.

Luzarraga is also a first chair trial lawyer in product liability and personal injury cases involving automotive companies, consumer product manufacturers, trace benzene and asbestos litigation as well as commercial litigation involving contract disputes, consumer claims, and professional liability.

With a practice focused on commercial litigation and the defense of product manufacturers in mass tort and products liability matters, Elan Hersh advises clients on electronic discovery (eDiscovery), information governance, litigation readiness and response, cross-border discovery issues, and data...

In addition to representing manufacturers in litigation through trial and appeal, Andrew counsels clients on risk mitigation and avoidance strategies, conducts product liability risk assessments, drafts warnings and product instructions, and advises clients on drafting warranties and commercial terms and conditionIn addition to representing manufacturers in litigation through trial and appeal, Andrew counsels clients on risk mitigation and avoidance strategies, conducts product liability risk assessments, drafts warnings and product instructions, and advises clients on drafting warranties and commercial terms and conditionin litigation through trial and appeal, Andrew counsels clients on risk mitigation and avoidance strategies, conducts product liability risk assessments, drafts warnings and product instructions, and advises clients on drafting warranties and commercial terms and conditions.

Product manufacturers and distributors will find no reprieve from this trend, as a 2009 study commissioned by the Defense Research Institute identified products liability as the leading growth area in tort litigation.

Demonstratives can frequently be used very effectively in product liability litigation, in which the issue is whether a product was manufactured negligently, causing harm — or in some cases, whether a product that was manufactured and used properly still caused harm to a consumer that leads to liability on the part of the manufacturer or seller.

Serve as national coordinating and trial counsel in product liability litigation for manufacturers of consumer and commercial products.

She has extensive experience in automotive, aviation, and pharmaceutical and medical device product liability litigation, and represents manufacturers of aircraft components, airframes, medical devices, pharmaceuticals, and other commercial and consumer products.

The attorneys of Steinbrecher & Span LLP have dedicated decades to defending manufacturers in lengthy, complex and multidistrict products liability litigation.

In addition to close to 30 years of trial experience in toxic tort litigation on behalf of asbestos manufacturers, Dan has also developed an extensive involvement in lead paint litigation on behalf of building owners and has also tried auto, premises, exercise equipment and various other product liability claims, representing manufacturers and insurerIn addition to close to 30 years of trial experience in toxic tort litigation on behalf of asbestos manufacturers, Dan has also developed an extensive involvement in lead paint litigation on behalf of building owners and has also tried auto, premises, exercise equipment and various other product liability claims, representing manufacturers and insurerin toxic tort litigation on behalf of asbestos manufacturers, Dan has also developed an extensive involvement in lead paint litigation on behalf of building owners and has also tried auto, premises, exercise equipment and various other product liability claims, representing manufacturers and insurerin lead paint litigation on behalf of building owners and has also tried auto, premises, exercise equipment and various other product liability claims, representing manufacturers and insurers.

He has focused his practice on complex, commercial, products liability and intellectual property litigation, with an emphasis on the defense of German and other European manufacturers in US courts.

Robert is a member of the Plaintiffs» Steering Committee for the Federal Multi-District Litigation surrounding five of the largest manufacturers of women's pelvic mesh products; In Re: Pelvic Repair System Products Liability Litigation (MDL's 2187; 2325; 2326; 2327; anproducts; In Re: Pelvic Repair System Products Liability Litigation (MDL's 2187; 2325; 2326; 2327; anProducts Liability Litigation (MDL's 2187; 2325; 2326; 2327; and 2387).

Brody, Hardoon, Perkins & Kesten, LLP has been defending product manufacturers, Distributors, and direct sellers in complex product liability litigation involving loss of life and property, serious personal injury and loss of business.

The Drug and Medical Device Product Liability Deskbook includes: detailed coverage of: warning - related claims and defenses; other information - based theories; strict liability; FDA - related per se liability; preemption of common law tort claims by the Food, Drug & Cosmetic Act and FDA regulations; class actions in drug and medical device litigation; theories of liability asserted against entities other than manufacturers; practical issues involving litigation management; the use of expert witnesses; and many other importanLiability Deskbook includes: detailed coverage of: warning - related claims and defenses; other information - based theories; strict liability; FDA - related per se liability; preemption of common law tort claims by the Food, Drug & Cosmetic Act and FDA regulations; class actions in drug and medical device litigation; theories of liability asserted against entities other than manufacturers; practical issues involving litigation management; the use of expert witnesses; and many other importanliability; FDA - related per se liability; preemption of common law tort claims by the Food, Drug & Cosmetic Act and FDA regulations; class actions in drug and medical device litigation; theories of liability asserted against entities other than manufacturers; practical issues involving litigation management; the use of expert witnesses; and many other importanliability; preemption of common law tort claims by the Food, Drug & Cosmetic Act and FDA regulations; class actions in drug and medical device litigation; theories of liability asserted against entities other than manufacturers; practical issues involving litigation management; the use of expert witnesses; and many other importanliability asserted against entities other than manufacturers; practical issues involving litigation management; the use of expert witnesses; and many other important topics.

He has represented some of America's largest manufacturing companies and financial institutions in their class action litigation throughout Florida and in Multi-District Litigation throughout the country, he advises companies and their Officers and Directors in company investigations and in corporate governance disputes, he represents businesses in disputes with their insurance carriers, and he has represented manufacturers and distributors in hundreds of toxic tort and products liabillitigation throughout Florida and in Multi-District Litigation throughout the country, he advises companies and their Officers and Directors in company investigations and in corporate governance disputes, he represents businesses in disputes with their insurance carriers, and he has represented manufacturers and distributors in hundreds of toxic tort and products liabilLitigation throughout the country, he advises companies and their Officers and Directors in company investigations and in corporate governance disputes, he represents businesses in disputes with their insurance carriers, and he has represented manufacturers and distributors in hundreds of toxic tort and products liability cases.

Our lawyers serve as trial counsel and as national coordinating counsel in complex products liability litigation, defending manufacturers of prescription and over-the-counter drugs and medical devices including orthopedic implants, antibiotics, contraceptives and antipsychotics.

At Field Law, our Litigation Practice Group has extensive experience representing manufacturers, distributors, installers and related entities involved in product liability lLitigation Practice Group has extensive experience representing manufacturers, distributors, installers and related entities involved in product liability litigationlitigation.

Sheryl Bjork concentrates her practice on the defense of complex mass tort product liability claims, representing some of the world's largest medical device and pharmaceutical manufacturers in individual, MDL, and class action litigation.